Qube Research & Technologies Ltd - CTI BIOPHARMA CORP ownership

CTI BIOPHARMA CORP's ticker is CTIC and the CUSIP is 12648L601. A total of 92 filers reported holding CTI BIOPHARMA CORP in Q1 2022. The put-call ratio across all filers is 0.84 and the average weighting 0.3%.

Quarter-by-quarter ownership
Qube Research & Technologies Ltd ownership history of CTI BIOPHARMA CORP
ValueSharesWeighting
Q1 2023$253,928
-66.5%
60,459
-62.8%
0.00%
-83.3%
Q1 2022$758,000
+715.1%
162,309
+331.4%
0.01%
+500.0%
Q4 2021$93,000
+27.4%
37,626
+52.4%
0.00%0.0%
Q3 2021$73,000
-39.7%
24,688
-40.6%
0.00%
-50.0%
Q1 2021$121,000
-78.0%
41,593
-75.6%
0.00%
-75.0%
Q4 2020$549,000170,5830.01%
Other shareholders
CTI BIOPHARMA CORP shareholders Q1 2022
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 6,535,674$27,449,8319.21%
Bleichroeder LP 3,893,730$16,353,6663.49%
AIGH Capital Management LLC 2,100,000$8,820,0003.25%
Ally Bridge Group (NY) LLC 550,000$2,310,0003.03%
Ghost Tree Capital, LLC 2,000,000$8,400,0002.48%
Bain Capital Life Sciences Investors, LLC 4,702,996$19,7532.47%
Altium Capital Management LP 850,000$3,570,0001.98%
Parkman Healthcare Partners LLC 1,753,630$7,365,2461.60%
BVF INC/IL 8,813,021$37,014,6881.35%
Sio Capital Management, LLC 526,239$2,210,2041.09%
View complete list of CTI BIOPHARMA CORP shareholders